Effects of CX516 on Functioning in Fragile X Syndrome and Autism
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will investigate whether CX516 can improve attention, memory, language, or
behavior in adults with Fragile X Syndrome and/or Autism.
CX516 is an AMPAKINE® compound. AMPAKINE compounds enhance synaptic strength. There is
evidence to suggest that the synapses in the brain of an individual with fragile X syndrome
are immature and abnormal. It is possible CX516 may partially correct this synaptic
transmission defect and lead to improvement in cognitive and behavioral functioning.
There is also reason to believe that these changes caused by CX516 could be helpful in
managing cognitive and behavioral symptoms in patients with autistic disorder.
Involvement for each participant will last 28 days. Participants will be given study
medication, a physical exam, and a variety of cognitive assessment tests to study potential
drug effectiveness at improving disease symptoms.